Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFS |
Texto Completo: | http://ri.ufs.br/jspui/handle/riufs/16325 |
Resumo: | A new coronavirus from the Coronaviridae family was identified in December 2019 as a cause of complications in the pulmonary pathways in humans, SARS-Cov-2. On February 26, 2020, the first case of infection was confirmed in Brazil, and since then a real war has started to fight the pandemic. This work was the first populationbased seroprevalence study on SARS-CoV-2 infection carried out in Sergipe. In this study we investigated the seroprevalence of antibodies against severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) in the state of Sergipe, Northeastern Brazil, using rapid IgM − IgG antibody test and fluorescence immunoassay during the first wave of the disease. in Brazil from July to August 2020. In order to identify gender and age group with the greatest applicability of rapid tests and evaluate the number of asymptomatic and symptomatic people, as well as the most presented symptoms. Seroprevalence was 9.3% (95% CI 8.5–10.1), 10.2% (95% CI 9.2– 11.3) for women and 7.9% (95% CI 6, 8–9.1) for men (p = 0.004). We found a decline in the prevalence of SARS-CoV-2 antibodies according to age, but the differences were not statistically significant: 0–19 years (9.9%; 95% CI 7.8–12.5), 20– 59 years (9.3%; 95% CI 8.4-10.3) and ≥60 years (9.0%; 95% CI 7.5-10.8) (p = 0.517). The metropolitan region had a higher seroprevalence (11.7%, 95% CI 10.3–13.2) than inland municipalities (8.0%, 95% CI 7.2–8.9) (P <0.001). These findings highlight the importance of serosurveillance in estimating the true impact of the COVID-19 outbreak and thereby providing data to better understand the spread of the virus, as well as providing information to guide stay-at-home measures and other policies. In addition, these results can be useful as baseline data to track the progress of the COVID-19 outbreak as social restraint initiatives begin to be relaxed in Brazil. |
id |
UFS-2_3677eea3a4e08a09196e959f49cadefd |
---|---|
oai_identifier_str |
oai:ufs.br:riufs/16325 |
network_acronym_str |
UFS-2 |
network_name_str |
Repositório Institucional da UFS |
repository_id_str |
|
spelling |
Santos, Anna Clara Ramos da SilvaAraújo, Adriano Antunes de Souza2022-09-21T13:57:14Z2022-09-21T13:57:14Z2022-02-28SANTOS, Anna Clara Ramos da Silva. Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe. 2022. 51 f. Dissertação (Mestrado em Ciências Farmacêuticas) – Universidade Federal de Sergipe, São Cristóvão, 2022.http://ri.ufs.br/jspui/handle/riufs/16325A new coronavirus from the Coronaviridae family was identified in December 2019 as a cause of complications in the pulmonary pathways in humans, SARS-Cov-2. On February 26, 2020, the first case of infection was confirmed in Brazil, and since then a real war has started to fight the pandemic. This work was the first populationbased seroprevalence study on SARS-CoV-2 infection carried out in Sergipe. In this study we investigated the seroprevalence of antibodies against severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) in the state of Sergipe, Northeastern Brazil, using rapid IgM − IgG antibody test and fluorescence immunoassay during the first wave of the disease. in Brazil from July to August 2020. In order to identify gender and age group with the greatest applicability of rapid tests and evaluate the number of asymptomatic and symptomatic people, as well as the most presented symptoms. Seroprevalence was 9.3% (95% CI 8.5–10.1), 10.2% (95% CI 9.2– 11.3) for women and 7.9% (95% CI 6, 8–9.1) for men (p = 0.004). We found a decline in the prevalence of SARS-CoV-2 antibodies according to age, but the differences were not statistically significant: 0–19 years (9.9%; 95% CI 7.8–12.5), 20– 59 years (9.3%; 95% CI 8.4-10.3) and ≥60 years (9.0%; 95% CI 7.5-10.8) (p = 0.517). The metropolitan region had a higher seroprevalence (11.7%, 95% CI 10.3–13.2) than inland municipalities (8.0%, 95% CI 7.2–8.9) (P <0.001). These findings highlight the importance of serosurveillance in estimating the true impact of the COVID-19 outbreak and thereby providing data to better understand the spread of the virus, as well as providing information to guide stay-at-home measures and other policies. In addition, these results can be useful as baseline data to track the progress of the COVID-19 outbreak as social restraint initiatives begin to be relaxed in Brazil.Um novo coronavírus da família Coronaviridae foi identificado em dezembro de 2019 como um causador de complicações nas vias pulmonares nos seres humanos, o SARS-Cov-2. No dia 26 de fevereiro de 2020 foi confirmado o primeiro caso de infecção no Brasil, e desde então se iniciou uma verdadeira guerra no combate a pandemia. Esse trabalho foi o primeiro estudo de soroprevalência de base populacional sobre a infecção pelo SARS-CoV-2 realizado em Sergipe. Neste estudo investigamos a soroprevalência de anticorpos contra síndrome respiratória aguda grave-coronavírus-2 (SARS-CoV-2) no estado de Sergipe, Nordeste do Brasil, usando teste rápido de anticorpos IgM − IgG e imunoensaio de fluorescência durante a primeira onda da doença no Brasil no período de julho a agosto de 2020. Afim de identificar gênero e faixa etária com a maior aplicabilidade de testes rápidos e avaliar o número de pessoas assintomáticas e sintomáticas, bem como os sintomas mais apresentados. A soroprevalência foi de 9,3% (IC 95% 8,5–10,1), 10,2% (IC 95% 9,2–11,3) para mulheres e 7,9% (IC 95% 6,8–9,1) para homens (p = 0,004). Encontramos um declínio na prevalência de anticorpos SARS-CoV-2 de acordo com a idade, mas as diferenças não foram estatisticamente significativas: 0–19 anos (9,9%; IC 95% 7,8–12,5), 20–59 anos (9,3%; IC 95% 8,4-10,3) e ≥60 anos (9,0%; IC 95% 7,5-10,8) (p = 0,517). A região metropolitana teve uma soroprevalência mais alta (11,7%, IC 95% 10,3–13,2) do que os municípios do inteior (8,0%, IC 95% 7,2–8,9) (P <0,001). Esses achados destacam a importância da sorovigilância para estimar o impacto real do surto de COVID-19 e, assim, fornecer dados para melhor compreender a propagação do vírus, além de fornecer informações para orientar as medidas de permanência em casa e outras políticas. Além disso, esses resultados podem ser úteis como dados básicos para acompanhar o progresso do surto de COVID-19 à medida que iniciativas de restrição social começam a ser flexibilizadas no Brasil.São CristóvãoporCOVID-19Inquéritos epidemiológicosSergipeEpidemiological inquiriesCIENCIAS DA SAUDE::FARMACIADeterminação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipeinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisPós-Graduação em Ciências FarmacêuticasUniversidade Federal de Sergipereponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSinfo:eu-repo/semantics/openAccessLICENSElicense.txtlicense.txttext/plain; charset=utf-81475https://ri.ufs.br/jspui/bitstream/riufs/16325/1/license.txt098cbbf65c2c15e1fb2e49c5d306a44cMD51ORIGINALANNA_CLARA_RAMOS_S_SANTOS.pdfANNA_CLARA_RAMOS_S_SANTOS.pdfapplication/pdf1778537https://ri.ufs.br/jspui/bitstream/riufs/16325/2/ANNA_CLARA_RAMOS_S_SANTOS.pdf84a9b9296e24f12d6003d22d35c310c1MD52TEXTANNA_CLARA_RAMOS_S_SANTOS.pdf.txtANNA_CLARA_RAMOS_S_SANTOS.pdf.txtExtracted texttext/plain71429https://ri.ufs.br/jspui/bitstream/riufs/16325/3/ANNA_CLARA_RAMOS_S_SANTOS.pdf.txt97c17f4407bfb8370651beb1b8351d4bMD53THUMBNAILANNA_CLARA_RAMOS_S_SANTOS.pdf.jpgANNA_CLARA_RAMOS_S_SANTOS.pdf.jpgGenerated Thumbnailimage/jpeg1588https://ri.ufs.br/jspui/bitstream/riufs/16325/4/ANNA_CLARA_RAMOS_S_SANTOS.pdf.jpgf2c150d6aa19bcc397cea101dd6df5f1MD54riufs/163252022-09-21 10:57:14.775oai:ufs.br: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Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2022-09-21T13:57:14Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false |
dc.title.pt_BR.fl_str_mv |
Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe |
title |
Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe |
spellingShingle |
Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe Santos, Anna Clara Ramos da Silva COVID-19 Inquéritos epidemiológicos Sergipe Epidemiological inquiries CIENCIAS DA SAUDE::FARMACIA |
title_short |
Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe |
title_full |
Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe |
title_fullStr |
Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe |
title_full_unstemmed |
Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe |
title_sort |
Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe |
author |
Santos, Anna Clara Ramos da Silva |
author_facet |
Santos, Anna Clara Ramos da Silva |
author_role |
author |
dc.contributor.author.fl_str_mv |
Santos, Anna Clara Ramos da Silva |
dc.contributor.advisor1.fl_str_mv |
Araújo, Adriano Antunes de Souza |
contributor_str_mv |
Araújo, Adriano Antunes de Souza |
dc.subject.por.fl_str_mv |
COVID-19 Inquéritos epidemiológicos Sergipe |
topic |
COVID-19 Inquéritos epidemiológicos Sergipe Epidemiological inquiries CIENCIAS DA SAUDE::FARMACIA |
dc.subject.eng.fl_str_mv |
Epidemiological inquiries |
dc.subject.cnpq.fl_str_mv |
CIENCIAS DA SAUDE::FARMACIA |
description |
A new coronavirus from the Coronaviridae family was identified in December 2019 as a cause of complications in the pulmonary pathways in humans, SARS-Cov-2. On February 26, 2020, the first case of infection was confirmed in Brazil, and since then a real war has started to fight the pandemic. This work was the first populationbased seroprevalence study on SARS-CoV-2 infection carried out in Sergipe. In this study we investigated the seroprevalence of antibodies against severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) in the state of Sergipe, Northeastern Brazil, using rapid IgM − IgG antibody test and fluorescence immunoassay during the first wave of the disease. in Brazil from July to August 2020. In order to identify gender and age group with the greatest applicability of rapid tests and evaluate the number of asymptomatic and symptomatic people, as well as the most presented symptoms. Seroprevalence was 9.3% (95% CI 8.5–10.1), 10.2% (95% CI 9.2– 11.3) for women and 7.9% (95% CI 6, 8–9.1) for men (p = 0.004). We found a decline in the prevalence of SARS-CoV-2 antibodies according to age, but the differences were not statistically significant: 0–19 years (9.9%; 95% CI 7.8–12.5), 20– 59 years (9.3%; 95% CI 8.4-10.3) and ≥60 years (9.0%; 95% CI 7.5-10.8) (p = 0.517). The metropolitan region had a higher seroprevalence (11.7%, 95% CI 10.3–13.2) than inland municipalities (8.0%, 95% CI 7.2–8.9) (P <0.001). These findings highlight the importance of serosurveillance in estimating the true impact of the COVID-19 outbreak and thereby providing data to better understand the spread of the virus, as well as providing information to guide stay-at-home measures and other policies. In addition, these results can be useful as baseline data to track the progress of the COVID-19 outbreak as social restraint initiatives begin to be relaxed in Brazil. |
publishDate |
2022 |
dc.date.accessioned.fl_str_mv |
2022-09-21T13:57:14Z |
dc.date.available.fl_str_mv |
2022-09-21T13:57:14Z |
dc.date.issued.fl_str_mv |
2022-02-28 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
SANTOS, Anna Clara Ramos da Silva. Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe. 2022. 51 f. Dissertação (Mestrado em Ciências Farmacêuticas) – Universidade Federal de Sergipe, São Cristóvão, 2022. |
dc.identifier.uri.fl_str_mv |
http://ri.ufs.br/jspui/handle/riufs/16325 |
identifier_str_mv |
SANTOS, Anna Clara Ramos da Silva. Determinação da soroprevalência da infecção pelo SARS-CoV-2 em Sergipe. 2022. 51 f. Dissertação (Mestrado em Ciências Farmacêuticas) – Universidade Federal de Sergipe, São Cristóvão, 2022. |
url |
http://ri.ufs.br/jspui/handle/riufs/16325 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.program.fl_str_mv |
Pós-Graduação em Ciências Farmacêuticas |
dc.publisher.initials.fl_str_mv |
Universidade Federal de Sergipe |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFS instname:Universidade Federal de Sergipe (UFS) instacron:UFS |
instname_str |
Universidade Federal de Sergipe (UFS) |
instacron_str |
UFS |
institution |
UFS |
reponame_str |
Repositório Institucional da UFS |
collection |
Repositório Institucional da UFS |
bitstream.url.fl_str_mv |
https://ri.ufs.br/jspui/bitstream/riufs/16325/1/license.txt https://ri.ufs.br/jspui/bitstream/riufs/16325/2/ANNA_CLARA_RAMOS_S_SANTOS.pdf https://ri.ufs.br/jspui/bitstream/riufs/16325/3/ANNA_CLARA_RAMOS_S_SANTOS.pdf.txt https://ri.ufs.br/jspui/bitstream/riufs/16325/4/ANNA_CLARA_RAMOS_S_SANTOS.pdf.jpg |
bitstream.checksum.fl_str_mv |
098cbbf65c2c15e1fb2e49c5d306a44c 84a9b9296e24f12d6003d22d35c310c1 97c17f4407bfb8370651beb1b8351d4b f2c150d6aa19bcc397cea101dd6df5f1 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS) |
repository.mail.fl_str_mv |
repositorio@academico.ufs.br |
_version_ |
1802110779041775616 |